The FDA has approved Repatha (evolocumab; Amgen) for use in addition to diet and maximally-tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical atherosclerotic cardiovascular disease, such as heart attacks or strokes, who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
The FDA has approved Praluent (alirocumab; Sanofi Aventis and Regeneron) injection.
Patients with greater variations in blood pressure over multiple office visits have a greater risk of cardiovascular disease (CVD) and all-cause mortality.
In the first major study of PTSD and cardiovascular disease (CVD) exclusively in women, patients who experienced traumatic events or developed PTSD had a significantly greater risk of CVD than those with no traumatic history or PTSD.
Use of proton pump inhibitors (PPIs) increase the risk of an adult experiencing a heart attack by 16-21% compared to those who don't use commonly prescribed antacids, a large study has found.
Moderate drinking may harm heart health in the elderly, and women appear to be at greater risk for this alcohol-related heart damage than men.
Obese patients taking warfarin have a higher risk of experiencing a bleeding event compared to their normal-weight counterparts, a new study suggests.
Previous research has yielded conflicting evidence on the use of digoxin in patient with atrial fibrillation (AF) or congestive heart failure (CHF), but the largest systematic review and meta-analysis suggests that there is an increased risk of all-cause mortality with digoxin use in these patients.